Latest Conference Coverage

Overviewing 36-Month, Phase 1b Data Testing Gene Therapy AB-1005 in Parkinson Disease: Nisha Chhabria MD, FAAN

The medical director of CNS Clinical Development at AskBio discussed long-term data presented at ATMRD from the company’s phase 1b assessing the investigational gene therapy AB-1005 in Parkinson disease. [WATCH TIME: 6 minutes]

Measuring Sleep Duration and Identifying Phenotypes Linked to Cognitive Decline in Hispanic Populations

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.

Evaluating Biomarkers to Guide Personalized Remyelination Strategies in MS: Ahmed Abdelhak, MD

At CMSC 2025, assistant professor of neurology at the University of California, San Francisco discussed progress on the integration of biomarkers into clinical practice for multiple sclerosis. [WATCH TIME: 4 minutes]

Phase 2 GABriella Study Represents First Step in Testing Selective Novel Y-Secretase Modulators for Prodromal Alzheimer Disease

Researchers unveil promising findings from the GABriella trial, exploring a novel treatment for prodromal Alzheimer's disease at AAIC 2025.

Higher Levels of Postpartum Depression in Women With MS Raise Importance for Screening Efforts

A new study reveals higher rates of postpartum depression in women with multiple sclerosis, emphasizing the need for early screening and management strategies.

Reducing Sodium in Narcolepsy Treatment: Cardiovascular Insights From the XYLO Trial

Richard Kovacs, MD, PhD, chief medical officer for the American College of Cardiology, discusses interim XYLO trial results, highlighting how switching to low-sodium oxybate can significantly impact blood pressure and cardiovascular risk profiles in narcolepsy.

Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MD

The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]

NeuroVoices: Howard Fillit, MD, on AAIC 2025 Highlights in Alzheimer Disease Prevention, Biomarkers, and Therapeutics

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation recapped some of the notable recent developments in the Alzheimer disease field presented at the 2025 Alzheimer’s Association International Conference.

Targeting Amyloid-ß Oligomers With Investigational Alzheimer Disease Therapy Valiltramiprosate

Sam Gandy, MD, PhD, director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai, discussed his presentation on detecting toxic amyloid-β oligomers and their role in AD pathology at AAIC 2025.

AAIC 2025: Top Interviews and Key Takeaways

Discover groundbreaking insights from the 2025 Alzheimer’s Association International Conference, featuring expert interviews on innovative treatments and diagnostics.

Larger, More Controlled Studies Needed to Confirm Genistein’s Potential to Curve Alzheimer Cognition

A recent meta-analysis reveals genistein's potential to enhance cognitive function in prodromal Alzheimer, urging further research for validation.

Importance of Patient Selection and Future Therapies in Alzheimer Treatment

In the third episode, Salloway emphasizes the need for careful patient selection when prescribing donanemab to minimize serious risks, highlighting the value of the newly approved safer dosing regimen. Supported by Eli Lilly.

Real-World Analysis Shows Growing Use of Octave’s MS Disease Activity Test in Clinical Practice

A recent analysis highlights the increasing use of Octave's MSDA test in managing multiple sclerosis, showcasing its impact on treatment decisions and disease monitoring.

Maintaining Efficacy in Safer Donanemab Dosing Regimen

Dementia expert Stephen Salloway, MD, PhD, overviews the stepwise donanemab regimen approved by the FDA, citing how it not only reduces ARIA rates but preserves the same level of amyloid reduction as the original dosing. Supported by Eli Lilly.

Alzheimer Psychosis Agent ACP-204 Shows No Impact on Corrected QT Intervals in Phase 1 Analysis

New findings reveal ACP-204 shows no significant QT interval prolongation in healthy adults, supporting its safety for Alzheimer disease psychosis treatment.

Donanemab Dosing and ARIA Risk in TRAILBLAZER-ALZ 6

Expert Stephen Salloway, MD, discussed findings from the TRAILBLAZER-ALZ 6 study, highlighting how a stepwise donanemab dosing regimen significantly lowered rates of ARIA in early Alzheimer disease. Supported by Eli Lilly.

Monitoring Long-Term Efficacy of Migraine Wearable Device Over 3 Years: Alit Stark-Inbar, PhD

The corporate vice president of medical information and research at Theranica discussed long-term findings presented at AHS 2025 covering the company’s Nerivio remote electrical neuromodulation device for patients with migraine. [WATCH TIME: 5 minutes]

Advancing Neurodegenerative Disease Research With Innovative Targets and Platforms: Xiao Xu, PhD; Mark Carlton, PhD

Two experts from Cerevance discussed data from the company’s posters recently presented at AAIC 2025, which highlighted potential therapeutic targets for Alzheimer disease. [WATCH TIME: 5 minutes]

Targeting SIGLEC10 With ONC-841: A Novel Mechanism in Alzheimer Disease Treatment

Yang Liu, PhD, co-founder, CEO, and chief scientific officer of OncoC4, provided commentary on the rationale and promising preclinical data behind ONC-841, a novel anti-SIGLEC10 antibody targeting amyloid and tau in Alzheimer disease.

Highlighting Research Progress in Tau-Targeting Therapy for Alzheimer Disease: Diana Gallagher, MD

At AAIC 2025, the head of AD, MS and Immunology Development Units at Biogen discussed ongoing research efforts targeting tau pathology in AD, specifically the company's investigational candidate BIIB080. [WATCH TIME: 6 minutes]

Factors to Consider When Choosing the Right Disease-Modifying Therapy for Newly Diagnosed MS

Gabrielle Macaron, MD, assistant professor of neuroscience at Université de Montréal, discussed the nuanced clinical decision-making involved in initiating a DMT for patients newly diagnosed with MS.

NeuroVoices: John Hey, PhD, on Alzheimer Agent Valiltramiprosate and Its Promise in Mild Cognitive Impairment

The chief scientific officer at Alzheon discussed the mechanism of valiltramiprosate and new data on toxic amyloid oligomers presented at the recently concluded Alzheimer’s Association International Conference.

AAIC Presentation Highlights Improved Efficacy and Safety With Lecanemab Subcutaneous Autoinjector

New findings reveal the promising efficacy and safety of a subcutaneous lecanemab autoinjector for early Alzheimer disease treatment, enhancing patient care.

Prescription of Love, Mindfulness, and Hope in Parkinson Disease Care: Esther Labib-Kiyarash, MSHA, CPHQ

The advisory board member of the Parkinson's Foundation shared personal insights on how love, present-moment awareness, and hope shaped her approach to living with the Parkinson disease. [WATCH TIME: 6 minutes]

Reviewing the Power of Health and Wellness Coaching in Multiple Sclerosis Care

At CMSC 2025, Cassandra Moore, MPH, CPH, associate vice president of strategy and innovation at the National MS Society, discussed the impact of health and wellness coaching in patients with multiple sclerosis.

Understanding Tau Aggregation in Alzheimer Disease and Related Dementias: Maria Grazia Spillantini, PhD

The professor of molecular neurology at the University of Cambridge highlighted recent research on tau protein aggregation in Alzheimer disease and other related tauopathies. [WATCH TIME: 6 minutes]

AAIC Presentations Provide Context on Lecanemab’s Real-World Effect 2 Years Since Approval

A real-world study reveals lecanemab's effectiveness in early Alzheimer's, showing stability or improvement in 83.6% of patients after two years.

Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study

Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.

Anti-Tau Agent Bepranemab Slows Tau Accumulation in Phase 2 TOGETHER Trial

UCB's bepranemab shows promise in slowing tau accumulation in early Alzheimer disease, marking an advancement in tau-targeted therapies.

Phase 3 Study Results of Obicetrapib on Alzheimer Disease Biomarker Progression: Philip Scheltens, MD, PhD

The Emeritus Professor of Cognitive Neurology at VU University Medical Center talked about findings presented at AAIC 2025 from the phase 3 BROADWAY trial of obicetrapib in Alzheimer disease. [WATCH TIME: 3 minutes]